A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
ConditionAtopic Dermatitis (AD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChengdu Kangnuoxing Biopharma,Inc.
About this trial
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Eligibility criteria
Qualifiers
Trial participants aged 18 years or older at baseline, with no restrictions on gender.
Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.
Disqualifiers
Known history of allergic reaction to Stapokibart Injection.
Trial participants currently or plan participating in any interventional clinical trial.
Trial participants with hematologic malignancies.
Women with pregnant.
Trial design
Treatments tested in this trial
- Stapokibart
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov